
Notícias da Genzyme
Genzyme
| August 25, 2008 | Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria | | August 6, 2008 | Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen | | July 23, 2008 | Genzyme Reports Strong Second-Quarter Growth | | July 17, 2008 | Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases | | June 24, 2008 | Genzyme and Isis complete licensing of mipomersen | | June 17, 2008 | Genzyme Files Applications for Approval of Mozobil in the United States and Europe | | June 2, 2008 | Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients | | May 7, 2008 | Preliminary Results from Phase 2 Genzyme Study | | April 25, 2008 | FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen | | April 23, 2008 | Genzyme Reports Strong First-Quarter Growth | | April 22, 2008 | Genzyme to Build New R&D Center in Beijing | | April 21, 2008 | Genzyme Provides Update on Myozyme® Manufacturing | | April 14, 2008 | Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy | | March 19, 2008 | Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients | | March 10, 2008 | Genzyme Announces Presentation of New Positive Data on Carticel® | | March 6, 2008 | Genzyme Launches Renvela® in the U.S. for Dialysis Patients | | February 13, 2008 | Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year | | February 1, 2008 | University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program | | February 1, 2008 | Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration | | January 15, 2008 | Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic | | January 8, 2008 | Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue | | January 7, 2008 | Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen | | December 19, 2007 | Genzyme Receives European CE Mark for Single-Treatment Synvisc-One™ | | December 17, 2007 | Genzyme Announces FDA Approval of Thyrogen® For Use In Thyroid Cancer Ablation | | December 13, 2007 | Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints | | December 5, 2007 | Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML | | December 4, 2007 | National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment | | November 13, 2007 | Genzyme Receives FDA Response Letter on Synvisc-One™ | | October 29, 2007 | Epicel™ Wins Marketing Approval for Severe Burn Victims | | October 25, 2007 | Genzyme and Sunway to Collaborate on Gene Therapy Program in China | | October 24, 2007 | Genzyme Reports Strong Earnings Growth in Third Quarter | | October 23, 2007 | Genzyme Launches Cholestagel® in Europe | | October 22, 2007 | Bioenvision Shareholders Approve Acquisition by Genzyme Corporation | | October 22, 2007 | FDA Approves Genzyme's Renvela™ for Dialysis Patients | | October 16, 2007 | Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease | | October 15, 2007 | Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis | | October 12, 2007 | Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease | | October 12, 2007 | Genzyme Recognized by Scientists as a Top Employer | | October 10, 2007 | Delaware Court Approves Bioenvision, Genzyme Joint Petition | | October 10, 2007 | Bioenvision and Genzyme File Petition in Delaware Court | | October 4, 2007 | Genzyme Receives Approval to Market Elaprase® in Japan | | September 27, 2007 | Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share | | September 26, 2007 | Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis | | September 20, 2007 | FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia | | September 18, 2007 | Genzyme Begins Major Expansion of Boston Manufacturing Facility | | August 29, 2007 | Genzyme Announces Publication of DCOR Study in Kidney International | | July 23, 2007 | Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases |
|
 |
 |
 |
INFORMAÇÕES DE CONTATO: |
 |
Genzyme do Brasil Ltda.
São Paulo
Av. Francisco Matarazzo, 1400
10º andar - Conj. 101 - Edifício Milano
Água Branca
05001-903 - São Paulo – SP
SAC: 0800 77 123 73
Tel: +55 (11) 3874-9950
Fax: +55 (11) 3874-9952
São Paulo
Rua Padre Chico, 224
Vila Pompéia
05008 - 010 - São Paulo – SP
Tel: +55 (11) 3872-5761
Rio de Janeiro
Praça Floriano, 19 - 26º andar – Centro
20031-050 - Rio de Janeiro – RJ
Tel: +55 (21) 2156-9950
Fax: +55 (21) 2156-9952
Envie-nos um email
Genzyme de Argentina S.A.
Fondo de la Legua 161
(B1609JEB) Boulogne,
Provincia de Buenos Aires,
Argentina
T: + 54 11 4708-6900
F: + 54 11 4700-8111
www.genzyme.com.ar
Genzyme Chile Ltda.
Santiago de Chile
T: + 54 11 4708-6900
www.genzyme.cl
Genzyme de Colombia S. A.
Calle 93 B #17–25/49, Piso 5
Bogotá, Colombia
T: + 57 1 621 6600
F: + 57 1 621 6677
www.genzyme.com.co
Genzyme México S. de R.L. de C.V.
Paseo de la Reforma 505
Piso 49 Col. Cuauhtémoc
México Distrito Federal, C.P. 06500
México
T: + 52 55 5241 0600
F: + 52 55 5241 0659
www.genzyme.com.mx
|
 |
 |
|